AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

ConcertAI has announced an agreement with Bayer that allows the latter to utilise its Translational360 and AI SaaS solutions.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

TNF and Renova Health are set to use AI and ML for the identification of high-risk subjects who could benefit from GLP-1 ...

DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting it exclusive rights to leverage its antibody ...

The public cash offer, via a newly formed company by KKR called RWK BidCo, is for Skr145 per share in Biotage. The offer, ...